The global pharmaceutical industry experienced a 1% drop in company filings mentions of orphan designated drugs in Q3 2023 compared with the previous quarter, with the highest share accounted for by Sarepta Therapeutics, according to GlobalData’s analysis of over 51 pharmaceutical company filings. GlobalData’s Pharma: Filings Trends & Signals Q3 2023 report delves into earnings call transcripts and quarterly reports within the pharmaceuticals industry, extracting trends, signals, and comparative data to help businesses assess their performance, identify competitive intelligence, evaluate risks, and gain a comprehensive understanding of key industry events. Buy the report here.
Notably, orphan designated drugs was one of the most frequently referenced themes in Q3 2023, ranking highest in terms of mentions, ahead of social and industrial automation, according to GlobalData.
Of the top leading companies in the pharmaceutical industry, Sarepta Therapeutics had the greatest increase in references for orphan designated drugs in Q3 2023, compared with the previous quarter. GlobalData identified two orphan designated drugs-related sentences in the company's filings - 0.2% of all sentences - and remained flat of 0% in Q3 2023 compared with Q3 2022. BioMarin Pharmaceutical’s mentions of orphan designated drugs to 1.
GlobalData’s Company Filings Analytics also applies sentiment weight to reference sentences, based on whether the sentences are positive, negative, or neutral. Starting at 100 in 2020, an index over 100 is more positive. The overall index for orphan designated drugs in Q3 2023 was 119.
For further understanding of GlobalData's Pharma: Filings Trends & Signals Q3 2023, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.